From susceptibility to clinical action in fibrotic interstitial lung disease: determinants, progression, and evidence boundaries

Fibrotic interstitial lung diseases (ILDs) differ in their likelihood and rate of progression. This narrative review examines persistent injury, failed alveolar repair and feedback that sustains fibrosis, then relates these processes to clinical decisions. Causal mechanistic evidence comes mainly from mouse experiments and cell models; human tissue studies, often in advanced idiopathic pulmonary fibrosis (IPF), establish disease relevance but rarely the temporal sequence. Comparable mechanisms in hypersensitivity pneumonitis, autoimmune ILD and treatment-related injury require disease-specific validation. We assess susceptibility, progression after diagnosis and treatment benefit as separate questions. Genetic and telomere findings can inform counselling or treatment safety, whereas antigen investigation and avoidance address a potential source of ongoing injury. Imaging, bronchoalveolar lavage and systemic inflammatory activity can inform assessment in selected non-IPF diseases, but no validated rule uses these features to choose immunosuppression over antifibrotic therapy. Randomized trials support treatment in defined IPF, autoimmune ILD and progressive pulmonary fibrosis populations, principally through effects on lung function. Unsuccessful integrin-targeting trials also show that pathway plausibility does not establish clinical benefit or safety. Clinical action should therefore follow the underlying diagnosis, documented course and treatment indication, with explicit attention to toxicity and the outcome actually studied.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-16
DOI
https://doi.org/10.3389/fmed.2026.2026245
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

From susceptibility to clinical action in fibrotic interstitial lung disease: determinants, progression, and evidence boundaries

Yiqing ZHANG, Chunhua Yan, Zhijun Chen, Zhuohui Qin et al.
Frontiers in Medicine
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
article

From susceptibility to clinical action in fibrotic interstitial lung disease: determinants, progression, and evidence boundaries

Yiqing ZHANG, Chunhua Yan, Zhijun Chen, Zhuohui Qin, Lingli Luo, Ruijie Han
article en

Abstract

Fibrotic interstitial lung diseases (ILDs) differ in their likelihood and rate of progression. This narrative review examines persistent injury, failed alveolar repair and feedback that sustains fibrosis, then relates these processes to clinical decisions. Causal mechanistic evidence comes mainly from mouse experiments and cell models; human tissue studies, often in advanced idiopathic pulmonary fibrosis (IPF), establish disease relevance but rarely the temporal sequence. Comparable mechanisms in hypersensitivity pneumonitis, autoimmune ILD and treatment-related injury require disease-specific validation. We assess susceptibility, progression after diagnosis and treatment benefit as separate questions. Genetic and telomere findings can inform counselling or treatment safety, whereas antigen investigation and avoidance address a potential source of ongoing injury. Imaging, bronchoalveolar lavage and systemic inflammatory activity can inform assessment in selected non-IPF diseases, but no validated rule uses these features to choose immunosuppression over antifibrotic therapy. Randomized trials support treatment in defined IPF, autoimmune ILD and progressive pulmonary fibrosis populations, principally through effects on lung function. Unsuccessful integrin-targeting trials also show that pathway plausibility does not establish clinical benefit or safety. Clinical action should therefore follow the underlying diagnosis, documented course and treatment indication, with explicit attention to toxicity and the outcome actually studied.

Frontiers in MedicineVol. 13
Zhuhai People's Hospital (CN), Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine (CN), The People's Hospital Medical Group of Xiangzhou Zhuhai (CN)
Good health and well-being
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon